Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes.

Botulinum toxin-A (BTX) therapy is often used in cosmetology and to treat neuromuscular conditions. However, its therapeutic effects weaken as the neuromuscular junction heals, necessitating ...

The clinical benefits of botulinum toxin therapy in the treatment of various clinical disorders characterized by muscle hyperactivity, such as spasticity, was established more than 10 years ago by ...

0 Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids Patti R, Arcara M, Bonventre S, et al Br J Surg. 2008;95:1339-1343 ...

Figure 1. Salivary gland protection with botulinum toxin and scopolamine during tandem PSMA-targeted radioligand therapy. Pre-treatment 68Ga-PSMA PET/CT demonstrated comparable tracer uptake in ...

Gigagen Inc., a subsidiary of Grifols SA, has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy ...

BioWorld - Monday, October 14, 2024 Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards See today's BioWorld Science Home » BARDA awards Gigagen contract to develop therapy for botulinum ...